Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06145854 · ClinicalTrials.gov registry record
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
A clinical trial of HIV, sponsored by Midway Specialty Care Center.
- Active
- Registry status
- 100
- Enrollment target
- 3
- Study locations
NCT06145854 is a study of HIV that is active but no longer recruiting, run by Midway Specialty Care Center. The registered enrollment target is 100 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06145854, a study of HIV, is active but no longer recruiting, sponsored by Midway Specialty Care Center.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Conditions Studied
Interventions
- DRUG Cabotegravir Injection [Apretude]
Study Locations (3)
Florida
- Midway Specialty Care Center - Orlando
- Midway Specialty Care Center - Temple Terrace
- Midway Specialty Care Center - West Palm Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2027-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06145854
The ClinicalTrials.gov registry entry for NCT06145854 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The listed sponsor is Midway Specialty Care Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Cabotegravir Injection [Apretude] is the first listed.
NCT06145854 reports 3 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06145854 about?
NCT06145854 is a clinical study titled "Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP". Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will eva...
What is the current status of trial NCT06145854?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2024-01-02. Estimated completion is 2027-03-31.
What conditions does trial NCT06145854 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT06145854?
The interventions under investigation include: Cabotegravir Injection [Apretude] (DRUG).
Who is sponsoring clinical trial NCT06145854?
This trial is sponsored by Midway Specialty Care Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06145854 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transitional Housing and HIV Health
RECRUITING
-
Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
RECRUITING · Phase 1
-
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants
RECRUITING
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.